

Table 1 – Study population and baseline data.

	TF	TC	Pooled
<b>Allocated to vaccine group</b>	<b>204 (100%)</b>	<b>204 (100%)</b>	<b>408 (100%)</b>
Subjects available at:			
Month 1 follow up visit	203 (99.5%)	203 (99.5%)	406 (99.5%)
Month 2 follow up visit	197 (96.6%)	198 (97.1%)	395 (96.8%)
Month 7 follow up visit	188 (92.2%)	187 (91.7%)	375 (91.9%)
<b>Discontinued overall</b>	<b>16 (7.8%)</b>	<b>17 (8.3%)</b>	<b>33 (8.1%)</b>
Lost to follow-up	16 (7.8%)	17 (8.3%)	33 (8.1%)
<b>Immunogenicity/Safety population at Month 7</b>	<b>188 (92.2%)</b>	<b>187 (91.7%)</b>	<b>375 (91.9%)</b>
Male <sup>a</sup>	110 (53.9%)	106 (52.0%)	
Female <sup>a</sup>	94 (46.1%)	98 (48.0%)	
Birth weight (mean ± SD, g) <sup>a</sup>	3301.0 (412.0)	3285.3 (421.5)	
Range	2600 - 4100	2600 - 4100	
<b>Concomitant vaccine administration during 1 to 6 months</b>			
None	167 (84.8%)	172 (86.9%)	339 (85.8%)
Pentaxim <sup>b</sup>	14 (7.1%)	16 (8.1%)	30 (7.6%)
Rotarix <sup>c</sup>	16 (8.1%)	10 (5.0%)	26 (6.6%)

<b>Concomitant vaccine administration during 6 to 7 months</b>			
None	164 (87.2%)	161 (86.1%)	325 (86.7%)
Pentaxim <sup>b</sup>	13 (6.9%)	19 (10.2%)	32 (8.5%)
Rotarix <sup>c</sup>	11 (5.9%)	7 (3.7%)	18 (4.8%)

SD = standard deviation

<sup>a</sup>No differences between groups were statistically significant; <sup>b</sup>pentavalent vaccine against diphtheria, tetanus, pertussis, poliomyelitis and *Haemophilus influenzae* type b infections; <sup>c</sup>vaccine against rotavirus infections